A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Study of ION-682884 (SC) in patients with TTR Amyloidosis Polyneuropathy
Sponsor: Ionis Pharmaceuticals, Inc. Ionis
Enrolling: Male and Female Patients
IRB Number: AAAS6519
U.S. Govt. ID: NCT04136184
Contact: Jorge Cabrera or Raisy Fayerman: 212-305-6035 / jec2273@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the efficacy and safety of ION-682884 given for 24 months in patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) also known as Familial Amyloid Polyneuropathy (FAP), and determine if it can help people with mild or moderate polyneuropathy. To be in this study you must have FAP and be able to walk either with or without help.
This study is closed
Thomas Brannagan, MD
Do You Qualify?
Are you between 18 and 82 years old? Yes No
Are you willing to use contraceptive methods and are you non-pregnant and non-lactating? Yes No
Do you ambulate with or without assistance? Yes No
Do you have a diagnosis of hereditary transthyretin-mediated polyneuropathy? Yes No
Are you willing to adhere to vitamin A supplementation? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Jorge Cabrera or Raisy Fayerman